Venture Kick

Unomr develops novel nano-​micro technology based sensing approaches for diagnostics and drug discovery.

REMUUN is a biotechnology company focused on revolutionizing the development of therapeutic antibodies. It has created the MEGA platform, which mimics natural antibody gene modification and employs AID-based gene editing. This technology enables clients to accelerate, reduce costs, and enhance precision in the creation of monoclonal antibody therapies.

Azure Cell Therapies is a biotech company developing next-gen CGTs for neurodegenerative diseases

BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments

Shape Biopharmaceuticals is dedicated to developing immunotherapeutic drugs aimed at treating chronic diseases that currently have limited treatment options. The company utilizes advanced protein design and formulation technologies to create a new generation of immunotherapies that address unmet medical needs. By focusing on genetically driven conditions, Shape Biopharmaceuticals seeks to enhance patient outcomes and provide hope for individuals who lack effective therapeutic alternatives.

Nerai Bio is a biotechnology company that specializes in advancing genetic therapies. It operates an AI-assisted CRISPR protein engineering platform, enabling clients to enhance the development of next-generation therapeutic systems.

Translation-X is a biotechnology company specializing in the development of innovative therapeutics for Autism Spectrum Disorders (ASD). It employs a precision medicine strategy to target core symptoms of ASD, such as social interaction difficulties, aiming to provide effective treatment options for affected individuals.

ValTech Lifesciences is a medtech startup promoting cardiovascular health through its proprietary heart valve characteristics that improve the performance of mechanical and biological prostheses.

Abrinca Genomics is a biotechnology company specializing in the development of a web-based platform for managing and analyzing microbial genomics data. The platform is designed to be self-hosted, scalable, and dataset-independent, allowing researchers and bioinformaticians to securely organize, explore, and analyze vast volumes of microbial genome data. It supports multiple annotation formats, offers flexible access controls, and integrates seamlessly into existing workflows.

Amporin Pharmaceuticals seeks to create a new class of small-molecule medications that block and eradicate harmful soluble oligomers and holes found within cell membranes.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

TrueYouOmics specializes in comprehensive blood testing services, leveraging multi-omics and artificial intelligence to identify disease risks and facilitate preventive health planning. The company's innovative approach involves analyzing an individual's DNA, RNA, and protein data, then integrating these insights with medical knowledge graphs to estimate personalized disease risks. This holistic health assessment empowers individuals to proactively manage their well-being by taking preventive measures.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing to its clients.

Procavea Biotech specializes in developing a drug delivery platform centered on non-viral protein cages. This innovative platform is tailored for veterinary professionals, aiming to streamline and improve the efficiency of veterinary practice management. By providing a comprehensive solution, Procavea Biotech enhances overall operational effectiveness, enabling veterinary services to be delivered more seamlessly and integrated. Through its advancements, the company seeks to elevate the quality of care in veterinary practices.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Transpire Bio is a biotechnology platform focused on the development of inhaled therapeutics aimed at improving global health. The company specializes in creating lower-cost generic alternatives for injectable drugs, enhancing patient access to essential medications. Its portfolio includes medicines and inhalation therapies designed for treating lung diseases as well as systemic conditions, utilizing a painless delivery method to improve patient experience and adherence to treatment. Through its innovative approach, Transpire Bio seeks to make significant advancements in the field of inhalation therapies.

Gaia Technologies specializes in upcycling agricultural sidestreams, particularly olive waste, into valuable bio-compounds and ingredients for the cosmetics, food, and feed industries. By employing a modular and scalable extraction process, Gaia addresses the growing demand for natural alternatives to synthetic compounds while helping primary sector firms create new value streams and minimize their environmental impact. The company's innovative approach is built on insights from the EIT Food project Phenoliva, enabling the commercialization of products such as antioxidants, biochar, activated carbon, and biogas. This technology not only supports a circular economic model within food production but also positions Gaia as a cost-effective solution provider in the agro-based technology sector.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing to its clients.

ASTRA Therapeutics is a biopharmaceutical company specializing in the development of novel therapies for parasitic diseases. It leverages advanced scientific and technological approaches to identify and advance new treatment candidates for a wide range of parasitic disorders, including malaria, cryptosporidiosis, and toxoplasmosis.

metaLead Therapeutics is focused on developing a novel peptide medication aimed at transforming the treatment of metal-related diseases, particularly lead poisoning. The company’s innovative approach involves a peptide that selectively binds to lead ions while preserving essential metal ions. This specificity ensures the medication remains highly stable and effective, allowing for administration through both oral and intravenous routes. By targeting lead poisoning, metaLead Therapeutics aims to provide a significant improvement in detoxification methods for individuals affected by this condition worldwide.

Tandem Therapeutics is a biopharmaceutical company dedicated to pioneering treatments for fibrotic diseases. It focuses on the extracellular matrix (ECM), a network of proteins that surrounds cells, and develops peptide therapeutics called Matrix Targeting Peptides (MTPs) to target and treat the ECM barrier. By advancing research in ECM biology and its role in fibrotic conditions, including cancers and organ fibrosis, Tandem aims to provide more precise and effective treatment options for patients suffering from these diseases.

Adularia is a microbial-based therapy for Colorectal cancer.

Aukera Therapeutics is a biotechnology company focused on developing innovative therapeutics for patients affected by diseases related to the mTOR protein, including cancer and neurodegenerative disorders. Originating as a spin-off from the Biozentrum of the University of Basel, Aukera Therapeutics has established a pharmaceutical drug discovery engine that creates selective inhibitors of the mTOR complex. This technology aims to target various branches of the mTOR pathway, facilitating the development of treatments that not only address cancer but also manage the overactivity of the mTORC1 complex, which is crucial for regulating cell growth. Through its research and development efforts, Aukera Therapeutics strives to provide effective therapeutic options for patients with these challenging conditions.

Biosimo is a chemical engineering start-up focused on producing bio-based platform chemicals through innovative processes. The company aims to develop sustainable chemicals by utilizing advanced catalytic reactions and purification techniques. Its flagship technology replaces traditional production methods of acetic acid, which typically rely on coal and gas, with a novel approach that uses ethanol derived from biomass and waste. This shift not only supports the chemical, pharmaceutical, and material industries but also provides a direct alternative to fossil-based resources, promoting a more sustainable chemical production landscape.

Synature, a Swiss startup based at EPFL Innovation Park, specializes in measuring biodiversity using bioacoustics. The company deploys automated, autonomous recorders that capture audio data from nature, then employs AI and signal processing to analyze these recordings. Synature's offerings include a user-friendly dashboard that presents the data in an accessible format, enabling clients to monitor ecosystems and quantify their health.

Maven Health is a health tech company that provides an end-to-end metabolic health solution designed for healthcare providers. It specializes in assessing individuals' metabolic health using saliva as the bio-fluid for metabolite measurements. These measurements are analyzed with advanced Nuclear Magnetic Resonance (NMR) spectrometers employing custom analytical methods. The system is designed to be minimally invasive and cost-effective, assisting healthcare professionals in identifying at-risk individuals who may not be recognized through traditional healthcare practices. The results are delivered through an intuitive data platform, facilitating better decision-making and patient care.

FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on endometriosis. The company aims to accelerate the journey toward effective cures by addressing significant healthcare needs and introducing novel solutions that enhance women's health. FimmCyte is dedicated to empowering women to take control of their health and tackle unmet medical needs associated with these conditions.

Suri BioTech is a biotechnology company focused on developing health-promoting bacterial strains aimed at alleviating bloating and intestinal discomfort. The company specializes in creating science-based probiotics, particularly for infant health, utilizing proprietary strains that reduce hydrogen gas production by intestinal microorganisms. This innovative approach has potential applications in various functional gastrointestinal disorders, including infant colic and lactose intolerance. By leveraging its biotech platform, Suri BioTech seeks to provide effective solutions for individuals suffering from gastrointestinal issues.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing to its clients.

NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.

Reactive Illumination proposes an innovative green way to convert any organic waste (biowaste, tyres etc.) to mainly solid carbon and energy-efficient gases like H2, CH4, etc. within seconds without any chemicals that can be collected and used.

Biosimo is a chemical engineering start-up focused on producing bio-based platform chemicals through innovative processes. The company aims to develop sustainable chemicals by utilizing advanced catalytic reactions and purification techniques. Its flagship technology replaces traditional production methods of acetic acid, which typically rely on coal and gas, with a novel approach that uses ethanol derived from biomass and waste. This shift not only supports the chemical, pharmaceutical, and material industries but also provides a direct alternative to fossil-based resources, promoting a more sustainable chemical production landscape.

inSEIT provides an integral service for enzyme immobilization, from the matching between enzymes and supports to the application and process scale-up.

Adularia is a microbial-based therapy for Colorectal cancer.

Adaptyv Bio is focused on developing a protein engineering platform that leverages cell-free synthetic biology and high-throughput nanofluidics. The company’s technology aims to identify new antibodies for various diseases by bridging the gap between computational predictions and experimental validation. This innovative approach enhances the ability of healthcare providers to improve patient outcomes through more effective therapeutic options.

Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.

Oncobit is focused on enhancing personalized cancer care through the development of precise and highly sensitive diagnostic and monitoring tests. The company combines technical expertise with proprietary software and engages in close clinical collaborations, initially concentrating on melanoma while maintaining the potential to expand its solutions to other cancer types. Oncobit's innovative approach aims to improve patient outcomes by providing comprehensive and sensitive tests that enable clinics to offer tailored therapies and diagnostics, ensuring that cancer monitoring keeps pace with advancements in treatment methodologies.

Bottneuro specializes in developing non-invasive therapies for patients with early to moderate-stage Alzheimer's Disease. The company utilizes its NENI technology platform to create stimulation protocols that employ electrical stimulation of neurons and glial cells in the brain. Additionally, Bottneuro's innovative brain therapy system incorporates plant-based components and features a 3D-printed cap designed for continuous monitoring and targeted delivery of active substances. This approach aims to address the specific needs of Alzheimer's patients, ultimately enhancing their quality of life and improving treatment outcomes.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

Nemosia is a company focused on the development of positron emission tomography (PET) tracers designed to diagnose neurological disorders. By leveraging advanced technology, Nemosia creates tracers that facilitate the early identification of neurodegenerative diseases. Their products utilize PET imaging to visualize N-methyl-D-aspartate (NMDA) receptors in the brain, allowing for timely intervention and management of neurological conditions. This innovative approach aims to enhance diagnostic capabilities and improve patient outcomes in the field of neurology.

ArcoScreen is a Swiss medtech company focused on developing a microfluidic discovery platform designed for drug screening that targets cell membrane receptors. This innovative platform provides a faster and more efficient method for conducting chip-based assays of G-protein coupled receptors (GPCRs). By allowing researchers to identify a drug's mode of action directly on patient cells, ArcoScreen’s technology tests the proteins involved in drug efficacy in a single assessment. This streamlined approach facilitates the research and treatment of various diseases, including cancer, Alzheimer's, and diabetes, enhancing the overall drug discovery process.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.

Abologix is a biopharmaceutical company focused on developing innovative therapies for oncology. The company specializes in creating monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. This treatment aims to provide options for patients who do not respond to conventional cancer therapies, addressing various oncological conditions. By advancing its research in this area, Abologix seeks to enhance treatment outcomes and improve the quality of care for cancer patients.

Neurosoft Bioelectronics specializes in the development of soft implantable electrodes designed to interface with the nervous system for diagnosing and treating neurological disorders. Based in Geneva, Switzerland, the company has created next-generation electrodes that are compliant and conformable, addressing the limitations of existing stiff devices. Their flagship product, SOFT ECoG, is a subdural electrode that records from and stimulates the brain's surface, enhancing recording quality and minimizing MRI artifacts. Neurosoft's technology promotes long-term bio-integration, adapting to both static and dynamic mechanics of neural tissue, which can improve therapeutic outcomes for patients and expand the applications of neural interfaces in clinical settings.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

Bionomous specializes in the development of a biotechnological device that automates the observation, analysis, and sorting of small biological entities. By integrating innovative micro-engineering design with machine learning techniques, Bionomous has created a system that facilitates the automatic inspection and sorting of miniature biological entities. This technology is particularly valuable for studies in genetics, development, behavioral biology, and toxicology, allowing biotech companies to streamline processes related to the visual inspection, sorting, and dispensing of these entities.

peakPCR develops Polymerase Chain Reaction (PCR) devices for research and private laboratories. peakPCR is a low-cost, small size device capable of performing real-time polymerase chain reaction (qPCR). PCR is a method widely used in molecular biology to duplicate DNA segments, with applications such as genotyping, mutation detection, forensics, and paternity testing. The Polymerase Chain Reaction (PCR) is a widely used molecular technique to make millions of copies of a DNA sample, with applications in a variety of fields such as medical diagnostics, biotechnology, and forensic sciences. We have analyzed the heat transfer limitations of conventional PCR machines. This has led to the design of a completely new sample holder with extremely high heating and cooling rates and a much lower sample volume, in order to cut analysis time from currently 1-2 h down to 10 minutes, and reagent consumption by 90%. Next to a first stand-alone desktop instrument, we have also developed a portable version that is battery-powered and that operates in conjunction with a smartphone. We aim to deploy these PCR devices to research and private laboratories at affordable prices.

Abologix is a biopharmaceutical company focused on developing innovative therapies for oncology. The company specializes in creating monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. This treatment aims to provide options for patients who do not respond to conventional cancer therapies, addressing various oncological conditions. By advancing its research in this area, Abologix seeks to enhance treatment outcomes and improve the quality of care for cancer patients.

Bloom Biorenewables Ltd is a Swiss company founded in 2019, focused on developing technology that transforms wood and agricultural waste into renewable materials as alternatives to petroleum. The company specializes in creating bio-based materials for the chemical industry, targeting various markets including fragrances, plastics, and textiles. By introducing innovative production methods for biorenewable products and fuels, Bloom Biorenewables aims to provide sustainable solutions that reduce reliance on fossil fuels and contribute to climate change mitigation.

LifeMatrix specializes in the development of biomimetic implants and bio-engineering technology aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company creates human cell-derived, off-the-shelf tissue-engineered implants that transform into living tissue after implantation, allowing them to grow and regenerate alongside the patient. This innovative technology addresses the limitations of traditional implants and is designed to enhance patient recovery. LifeMatrix's award-winning solutions are founded on over 20 years of extensive research, supported by multiple national and international grants, and validated through more than 100 peer-reviewed publications. Preclinical studies have demonstrated the safety and efficacy of these implants, paving the way for their clinical application.

Bionomous specializes in the development of a biotechnological device that automates the observation, analysis, and sorting of small biological entities. By integrating innovative micro-engineering design with machine learning techniques, Bionomous has created a system that facilitates the automatic inspection and sorting of miniature biological entities. This technology is particularly valuable for studies in genetics, development, behavioral biology, and toxicology, allowing biotech companies to streamline processes related to the visual inspection, sorting, and dispensing of these entities.

Nutrix is a Swiss health-tech company founded in 2019 and based in Basel. It specializes in developing a nanosensor that is placed on the tooth to measure glucose levels in saliva, providing a non-invasive method for users to monitor their health. This technology is integrated with an external application that tracks food intake and offers dietary advice, aiming to aid in the prevention of diabetes. Nutrix combines artificial intelligence with wearables to create cost-effective healthcare solutions. In 2025, the company plans to introduce CortiSense, a non-invasive cortisol monitoring sensor that has already received a CES Innovation Award, further expanding its portfolio of health monitoring technologies. Through its innovative approach, Nutrix enables users to manage their health conditions effectively without the need for frequent medical consultations.

Flowbone is a company based in Lausanne, Switzerland, specializing in injectable biomaterials designed for the minimal-invasive augmentation of fragile bones that are at high risk of fracture. Its innovative technology stimulates the body's self-healing capabilities, allowing for local repair of bone and restoration of natural strength without compromising bone mechanics or blood flow. Flowbone focuses on addressing the needs of patients suffering from chronic insufficiency fractures and aims to enhance bone health, particularly in spine surgery. The company envisions a future where the elderly can maintain a high level of independence and quality of life, free from the debilitating effects of fragility fractures.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

MimiX Biotherapeutics Sàrl, established in 2016 and based in La Tène, Switzerland, specializes in the development of biofabrication technology for therapeutic and diagnostic applications. The company focuses on creating an ultra-fast biomanufacturing process that enables the production of patient-specific biological tissue equivalents. This innovative approach supports regenerative medicine and personalized healthcare, allowing for tailored treatments that meet individual patient needs. By advancing tissue engineering techniques, MimiX Biotherapeutics aims to enhance the precision and effectiveness of medical interventions.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

GenKnowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By measuring DNA methylation biomarkers, the company provides insights into how diet, physical activity, tobacco use, and alcohol consumption influence individual health. GenKnowme aims to transform scientific research into practical applications, allowing health-conscious individuals to better understand their genetic predispositions and make informed lifestyle choices for proactive health management.

OptiChroniX is a Swiss digital health solution company focused on enhancing brain health through early intervention. The company develops digital health interventions that combine biomedical, behavioral, computing, and engineering research, which are accessible via smartphones. These interventions allow patients to personalize and monitor their brain health by integrating data from various wearables. By offering tailored coaching, OptiChroniX aims to improve health literacy and medication adherence, addressing modifiable risk factors linked to cognitive decline, particularly in patients with Alzheimer’s disease and related co-morbidities. The company's mission is to optimize lifestyle choices and make healthcare more effective, ultimately enhancing clinical outcomes and quality of life.

Terapet SA, founded in 2019 in Geneva, Switzerland, specializes in proton therapy, an advanced form of radiotherapy for cancer treatment. Established by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals, the company aims to provide precise tumor targeting while minimizing damage to adjacent healthy tissues. Terapet's innovative technology allows for a reduced radiation dose to surrounding healthy cells by administering high doses of protons that halt at specific depths within the patient. This capability enables medical professionals to monitor the proton dose in real-time and in three dimensions, making cancer treatment more effective and potentially more cost-efficient. The company has successfully demonstrated the feasibility of its concept and is in the process of developing an initial version for market launch.

Neurosoft Bioelectronics specializes in the development of soft implantable electrodes designed to interface with the nervous system for diagnosing and treating neurological disorders. Based in Geneva, Switzerland, the company has created next-generation electrodes that are compliant and conformable, addressing the limitations of existing stiff devices. Their flagship product, SOFT ECoG, is a subdural electrode that records from and stimulates the brain's surface, enhancing recording quality and minimizing MRI artifacts. Neurosoft's technology promotes long-term bio-integration, adapting to both static and dynamic mechanics of neural tissue, which can improve therapeutic outcomes for patients and expand the applications of neural interfaces in clinical settings.

deepCDR Biologics AG is a biotechnology company based in Basel, Switzerland, founded in 2018. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on the development of innovative biologics, deepCDR Biologics aims to enhance the effectiveness of therapeutic antibodies in the pharmaceutical industry.

Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.

deepCDR Biologics AG is a biotechnology company based in Basel, Switzerland, founded in 2018. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on the development of innovative biologics, deepCDR Biologics aims to enhance the effectiveness of therapeutic antibodies in the pharmaceutical industry.

Swiss Medical Union SA, founded in 2019 and based in Yverdon-les-Bains, Switzerland, specializes in healthcare technology focused on testing the interaction, efficiency, and safety of new medical products. The company manufactures Micro-Bioreactor equipment that allows for ex vivo testing with human organ and tissue models, enabling the selection of appropriate therapies tailored to individual patient needs. Additionally, Swiss Medical Union develops software that simulates organ activity, analyzes interactions between medical products and specific organs, and monitors real-time effects of treatments within the circulatory system. The company also provides clinical testing services aimed at supporting healthcare professionals in making informed clinical decisions, particularly in cancer treatment. Its offerings are designed to enhance therapeutic outcomes while minimizing the risks associated with unnecessary treatments.

Autonomyo is a Swiss company, founded in 2014 and based in Lausanne, that specializes in developing robotic rehabilitation solutions aimed at enhancing mobility for individuals with neurological gait disorders. The company offers a lightweight exoskeleton designed for robotically assisted gait training, which can be utilized in rehabilitation clinics as well as in home settings with remote monitoring capabilities. This technology is intended to increase accessibility and training intensity for users, enabling healthcare professionals to better support individuals with neuromuscular and motor disorders in regaining their freedom of movement. Autonomyo's team comprises engineers, developers, and healthcare professionals who are dedicated to improving the quality of life for those affected by gait impairments.

Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, enabling early intervention to prolong gestation and enhance neonatal health outcomes. Pregnolia serves pregnant women and gynecologists, aiming to ensure every woman experiences a happy, healthy, and informed pregnancy. The company's dedicated team, including Sabrina, Francisco, and Annette, is committed to completing clinical trials, navigating regulatory paths, and commercializing the device to support gynecologists in improving preterm birth risk assessment and management.

MaxWell Biosystems AG is an electronics and biotechnology company based in Zurich, Switzerland, dedicated to advancing neuroscience research and enhancing preclinical drug discovery. Founded in 2016, the company specializes in functional cell imaging platforms, most notably its MaxOne electrophysiology platform. This innovative system features a high-density microelectrode array with 26,400 electrodes and 1,024 low-noise readout channels, which allows for precise recording and stimulation of electrogenic cells in vitro. By enabling researchers to extract detailed single cell and network parameters, MaxWell's technology significantly accelerates the characterization of cellular functions, reducing the typical timeframe from several months to just a few weeks. This advancement aids in phenotypic screening as well as drug toxicity and efficacy testing.

Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.

Bloom Biorenewables Ltd is a Swiss company founded in 2019, focused on developing technology that transforms wood and agricultural waste into renewable materials as alternatives to petroleum. The company specializes in creating bio-based materials for the chemical industry, targeting various markets including fragrances, plastics, and textiles. By introducing innovative production methods for biorenewable products and fuels, Bloom Biorenewables aims to provide sustainable solutions that reduce reliance on fossil fuels and contribute to climate change mitigation.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

Microcaps AG is a company based in Zurich, Switzerland, specializing in the development of innovative microencapsulation technology. Founded in 2018, it focuses on creating a scalable production system for precise microcapsules and microparticles using advanced microfluidics. The company's devices enable the fabrication of monodisperse capsules and emulsions of various sizes, providing tailored solutions for drug delivery, probiotic encapsulation, and enhancing the stability of pharmaceutical agents and fragrances in cosmetic products. Microcaps aims to offer a fully automated encapsulation micro-factory that ensures size control and precise dosing, significantly improving production efficiency and throughput rates compared to conventional methods.

Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.

Alibion AG, founded in 2018 and based in Allschwil, Switzerland, specializes in drug discovery and the development of therapeutics. The company addresses the challenge of bringing innovative therapies from academic laboratories to patients by accelerating early-stage development. Alibion focuses on identifying promising new therapeutics and collaborates with outsourced partners to streamline the development process, thereby minimizing time and costs while ensuring compliance with quality standards. By doing so, Alibion aims to enhance the availability of novel treatments, ultimately improving patient outcomes on a global scale.

Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.

Mitoscreening platform (MSP) is used to screen metabolism-targeting anti-cancer drugs to discover.

GenKnowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By measuring DNA methylation biomarkers, the company provides insights into how diet, physical activity, tobacco use, and alcohol consumption influence individual health. GenKnowme aims to transform scientific research into practical applications, allowing health-conscious individuals to better understand their genetic predispositions and make informed lifestyle choices for proactive health management.

Evictas is a biotechnology company.

Viventis Microscopy is focused on developing an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples. This system includes both specialized hardware and custom microscope control software, allowing researchers to conduct extended imaging of delicate specimens such as embryos and organoids. By facilitating detailed observation of these samples, Viventis Microscopy aims to support researchers and organizations in accelerating drug development processes.

Prolongate is a protein drugs and biotech company.

Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.

ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

BIOMEM

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes microscopic worms for substance testing in pharmaceutical, chemical, and cosmetic industries. Their flagship product, the Caenorhabditis elegans-on-chip, integrates the use of these organisms for in vivo testing with a fully automated platform for in vitro culture, treatment, and analysis. This technology facilitates comprehensive toxicity testing, drug discovery, and anthelmintic testing applications, allowing clients to evaluate biological responses observable only at the whole-organism level. Nagi Bioscience aims to transform traditional testing methodologies by introducing its unique "Organism-on-Chip" technology.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Microcaps AG is a company based in Zurich, Switzerland, specializing in the development of innovative microencapsulation technology. Founded in 2018, it focuses on creating a scalable production system for precise microcapsules and microparticles using advanced microfluidics. The company's devices enable the fabrication of monodisperse capsules and emulsions of various sizes, providing tailored solutions for drug delivery, probiotic encapsulation, and enhancing the stability of pharmaceutical agents and fragrances in cosmetic products. Microcaps aims to offer a fully automated encapsulation micro-factory that ensures size control and precise dosing, significantly improving production efficiency and throughput rates compared to conventional methods.